PCSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Processa Pharmaceuticals Inc (PCSA) is not a strong buy for a beginner, long-term investor at this time. The lack of positive financial performance, no clear technical signals, and absence of significant catalysts make it prudent to hold off on investing in this stock.
The MACD is slightly positive at 0.0476, indicating mild bullish momentum, but the RSI at 52.867 is neutral. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 2.157, with resistance at 2.462 and support at 1.851. Overall, the technical indicators do not strongly suggest a buy.
NULL identified. No recent news or significant trading trends from insiders or hedge funds.
EPS dropped significantly by -92.99% YoY in the latest quarter, and the company continues to report negative net income (-$3,436,573). No recent news or events to drive positive sentiment.
In Q3 2025, revenue remained at $0 with no growth. Net income improved slightly by 1.53% YoY but remains negative at -$3,436,573. EPS dropped significantly by -92.99% YoY to -1.81, and gross margin remains at 0.
No data available for analyst ratings or price target changes.
